ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer

  • End date
    Oct 1, 2030
  • participants needed
  • sponsor
    University Hospital, Geneva
Updated on 24 January 2021
adenocarcinoma of prostate


The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.


Total dose and dose per fraction play an important role in the curative treatment of prostate cancer with radiotherapy (RT). Modern image guided external RT allows safe dose escalation of prostate cancer. There are strong radiobiological and clinical considerations that suggest that treatment with a small number of large fractions (hypofractionation) may increase the therapeutic ratio of RT for prostate cancer by increasing the tumor cell killing effect with relatively less toxic effect on the surrounding late responding normal tissues compared to conventional fractionation.

The question of how far can the number of fractions with SBRT be reduced is an exciting research matter with an undoubtful goal, face the challenge of assessing the potential for cure of prostate cancer patients with a single and unique fraction of high dose irradiation similar to what is already undertaken with radiosurgery against brain, lung, and liver targets.

We hypothesize that an ultra-hypofractionated single-dose SBRT employing state of the art of image-guided RT techniques may be feasible, with a safe toxicity profile and an optimal long-term tumor control. Hence, a prospective phase I/II clinical trial will be initiated in prostate cancer patients with a localized disease to validate this treatment schedule as an alternative to normofractionated/moderate hypofractionated RT schedules to be tested in a second time in a phase III trial.

Condition Malignant neoplasm of prostate, Prostatic disorder, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment Stereotactic body radition (SBRT)
Clinical Study IdentifierNCT03294889
SponsorUniversity Hospital, Geneva
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures
Histologically confirmed adenocarcinoma of the prostate without small cell features
Tumor clinical stage cT1c-2c, pN0 or cN0, M0, according to UICC TNM 2009
MRI staging must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c
Gleason score at biopsy 3+3 or 3+4 (WHO 2016 Grade Groups 1, 2)
PSA 15 ng/ml
WHO performance status 0-1
International Prostate Symptom Score 10 (alpha blockers allowed)
MRI-based volume estimation of prostate gland 70 cc
Patient agrees not to father a child during trial treatment and during 6 months thereafter

Exclusion Criteria

Tumor clinical stage cT3a-3b or T4
Evidence of T3a, T3b or T4 disease as assessed by MRI
Positive lymph-nodes or metastatic disease from prostate cancer on imaging studies
Significant tumor on the transitional zone as assessed by MRI
Gleason at biopsy 4+3
Androgen deprivation therapy or products known to affect PSA levels
Impossibility to implant Calypso beacons
History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration with the exception of curatively treated localized non-melanoma skin cancer
Prior pelvic radiotherapy
Previous surgery for prostate cancer
Previous transurethral resection of the prostate (TURP) (< 12 weeks before registration)
Hip prosthesis
Severe or active co-morbidity likely to impact on the advisability of SBRT
Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note